Sie sind hier

Startseite

Bukwang Pharmaceutical Co. Ltd.

Bukwang Pharmaceutical Co. Ltd. ist ein Südkorea Unternehmen, befindet sich in 398-1, Daebang-dong, Dongjak-gu. Mehr Einzelheiten sind wie folgt:

Unternehmensinformation

  • Name des Unternehmens: Bukwang Pharmaceutical Co. Ltd.
  • Land: South Korea
  • Adresse: 398-1, Daebang-dong, Dongjak-gu
  • Internationale Vorwahl: 82
  • Telefonieren: 02-828-8114 (+82-02-828-8114)
  • Fax: 02-828-8129 (+82-02-828-8129)
  • Kontakt: Lee,Seong Gu
  • Position: Ceo
  • Webseite:
  • Artikelliste: Coating Machines, Spectrophotometers
  • Arbeitnehmer: 101-500 Employees
  • Typ: Manufacturers
  • Gründungsjahr: 1960
  • Profil: Bukwang Pharmaceutical Co., Ltd., Which Is Well Known For The Anti-plaque Toothpaste That Opened The High-quality Toothpaste Era, Was Founded On The Seventeenth Of October, 1960. We Have Continually Strove For Excellent Medicine, Pursuing A Paradise Of Healthy Living. We Have Achieved Remarkable Growth For Over Forty Years. Now We Have 600 Employees Or So, With Approximately 160 Billion Won In Net Sales In The 2006 Fiscal Year. We Have Made More Than One Hundred Medicinal Products, Including 'feroba¢ç' For The Prevention And Treatment Of Iron Deficiency Anemia, 'coritussal¢ç' For Treatment Of Cough & Colds, 'alaxyl¢ç' For The Relief Of Symptoms Of Anorexia, Physconia And Anusol, 'parodontax¢ç' For Gingivitisand Symptoms Of Alveolar Pyrrhea, 'legalon¢ç' For Treatment Of Toxic Liver Damage, 'thioctacid¢ç' For Relief And Treatment Of Diabetic Neuropathy, 'azeptin¢ç' For Treatment Of The Symptoms Of Seasonal Allergies, 'somazina¢ç' For Moderate Severe Acute Ischemia And 'levovir¢ç' Cap.' For Chronic Hbv. Etc. We Developed 'levovir¢ç Cap(clevudine)' For The Treatment Of The Hepatitis B-virus, Recognizing That A Company Would Not Survive Without Continual R&d. As A Result, Eisai, The Japanese Company, Paid Us 44 Million Dollars For The Copyright For Clevudine Toward Asian Countries Including China, And Pharmasset, The U.s. Company, Paid 30 Million Dollars For The Copyright For Clevudine Toward The European And American Markets. In Last Year, Levovir Was Approved By Kfda. And This Is The 11th New Drug Developed In Korea. We Are Looking Forward To Its Being Merchandised Soon And Expect A Profit Of 20-30 Billion A Year In Korea. Our Goal Is To Sell 200 Billion A Year Within 4 Years Through Intensive Development Of New Products And Through Harmony Between Major Products And New Products. Since We Became Listed On The Stock Market In August, 1988, We Have Mainained Good Financial Management, So Many Consumers And Stockholders Have Loved And Trusted Us For A Long Time. We Also Expect To Be Free From Debt In The Near Future. Bukwang Pharm Is Reinvests A Part Of Its Profit For Continual Development Of New Medicine Products. We've Already Started New Projects To Develop New Medicines In The R&d Center, Which Recently Relocated To The Guro Digital Complex. We Are Sure That We Will Lead Biotechnology In The 21st Century, And Will Continue To Be Loved By Our Customers.
Weitere Links

  • Bukwang Medical Inc.
  • Bukwang Pharm. Ind. Co. Ltd.
  • Bukwang Pharmaceutical Co. Ltd.
  • Bukyoung Enginnering Co. Ltd.
  • Bukyung Lace Co. Ltd.

    •         ‹ vorherige Seite | nächste Seite ›
    • Zum Verfassen von Kommentaren bitte Anmelden.